Brief: Lantern Pharma Announces First Patient Dosed In Japan
19/11/2024 13:23
Nov 19 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA ANNOUNCES FIRST PATIENT DOSED IN JAPAN FOR
THE
EXPANSION COHORT IN THE PHASE 2 HARMONIC™ CLINICAL TRIAL OF
LP-300 IN NEVER-SMOKER NSCLC PATIENTS
Source text: ID:nBw6j2tYSa
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview